Business Overview: Kalaris Therapeutics, Inc. (NASDAQ: KLRS)

---

Executive Summary

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases, headquartered at 860 Broadway in New York City. The current company emerged from a 2025 reverse merger in which the privately held "Legacy Kalaris" combined with the publicly traded AlloVir, Inc., inheriting AlloVir's NASDAQ listing and a large cash balance that now funds Kalaris's ophthalmology pipeline. Kalaris's technology traces back to a 2021 license (amended 2022) with the University of California, San Diego, covering anti-VEGF fusion protein research originating from the lab of Dr. Napoleone Ferrara — the scientist credited with discovering the biology behind the blockbuster anti-VEGF eye drugs Lucentis and Avastin.

The company's lead candidate, TH103, is an intravitreal anti-VEGF fusion protein designed to treat neovascular age-related macular degeneration (nAMD), with ambitions to expand into diabetic eye disease, retinal vein occlusion, and retinopathy of prematurity. Kalaris matters because it is attempting to improve on the durability and tolerability of the current anti-VEGF standard of care — a multi-billion-dollar retinal disease market — using a next-generation molecule architecture, backed by an unusually strong cash position for a company of its size following the AlloVir merger.

Kalaris owns no manufacturing facilities and plans to commercialize any approved product through its own specialty retina-focused sales force, while outsourcing drug production to third-party contract manufacturers.

---

1. Core Business Model & How They Work

Kalaris's model is a classic clinical-stage biopharma value chain: in-license core biology, run the molecule through sequential human trials, and plan for an eventual specialty sales force rather than a broad primary-care launch.

UCSD License (Ferrara anti-VEGF IP)
            |
            v
   TH103 Preclinical Development
            |
            v
  Phase 1a Single Ascending Dose (nAMD)
     -> positive initial data, Dec 2025
            |
            v
 Phase 1b/2 Multiple Ascending Dose (started Q3 2025)
     -> preliminary data expected 1H 2027
            |
            v
     Planned Phase 3 Initiation (YE 2027)
            |
            v
  Third-Party Contract Manufacturing
            |
            v
 In-House Specialty Retina Sales Force (if approved)

---

2. Product Portfolio

---

3. Competitive Landscape

Kalaris competes directly with the dominant incumbents in retinal disease treatment — Roche (Vabysmo, Lucentis), Novartis, Regeneron (Eylea/Eylea HD), AbbVie, Eli Lilly, and Merck — as well as a wave of lower-cost aflibercept and ranibizumab biosimilars now eroding branded anti-VEGF pricing. It also faces clinical-stage rivals pursuing next-generation retinal therapies, including 4D Molecular Therapeutics, RegenxBio, EyePoint Pharmaceuticals, Ocular Therapeutix, Kodiak Sciences, and Ollin.

              High Clinical/Commercial Maturity
                          |
   Roche / Regeneron /    |
   Novartis (approved     |
   anti-VEGF franchises)  |
                          |
Low Differentiation ------+------ High Differentiation
                          |
   Biosimilars            |   Kalaris (TH103),
   (low-cost generics)    |   4DMT, EyePoint, Kodiak
                          |
              Low Clinical/Commercial Maturity

---

4. Strategic Strengths & Risks

Strengths:

• Differentiated pharmacology: early Phase 1a data show materially lower systemic drug exposure than approved anti-VEGF agents, a potential safety and dosing-frequency advantage.
• Strong, well-capitalized balance sheet: $118.0 million in cash at year-end 2025 (versus just $1.6 million a year earlier), funding operations into Q4 2027 and past key data readouts — unusually strong runway for a clinical-stage biotech.
• Pedigreed science: license rights trace to Dr. Napoleone Ferrara's UCSD research, lending scientific credibility to the mechanism.

Risks:

• Single-asset concentration: the company's value is almost entirely tied to TH103's success; a safety or efficacy failure in the ongoing Phase 1b/2 study would be existential.
• Manufacturing tolerability signal: two Phase 1a subjects experienced transient intraocular inflammation attributed to manufacturing-related host cell proteins, requiring process changes before further development.
• Crowded, well-funded competitive set: Roche, Regeneron, and Novartis have enormous commercial infrastructure and are simultaneously developing their own next-generation retinal therapies.
• No revenue and continued losses: as a pre-commercial biotech, Kalaris will need substantial additional capital beyond its current runway if trials are delayed or expanded.

---

5. Financial Overview

---

6. Summary Conclusion

Kalaris Therapeutics is a well-funded, single-asset clinical-stage ophthalmology company whose investment case rests almost entirely on TH103's ability to combine anti-VEGF efficacy with meaningfully lower systemic drug exposure than the current standard of care. Early Phase 1a data are encouraging on both efficacy and pharmacokinetics, and the AlloVir merger gave Kalaris a cash runway that is rare among clinical-stage peers. The next 18 months of Phase 1b/2 data will determine whether TH103 can differentiate itself against entrenched franchises from Roche, Regeneron, and Novartis and a growing field of next-generation retinal disease competitors.